Paul Hergenrother is the recipient of this year's UCB-Ehrlich Award for Excellence in Medicinal Chemistry. He was cited for outstanding contributions to chemical biology and anticancer drug discovery. He is a co-founder of the anticancer drug development company Vanquish Oncology.
The “UCB-Ehrlich Award for Excellence in Medicinal Chemistry” was established to acknowledge and recognise outstanding research in the field of Medicinal Chemistry in its broadest sense. The Award is given biennially and consists of a diploma, € 7.500 and an invitation to present a lecture at an EFMC-ISMC symposium.
The European Federation for Medicinal Chemistry (EFMC) is an independent association representing medicinal chemistry societies in Europe. Its objective is to advance the science of medicinal chemistry by promoting cooperation and networking, by providing training and mentoring, by rewarding scientific excellence, and by facilitating communication and influencing stakeholders.